MSB
MESOBLAST LIMITED ORDINARYMesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
MSB
MSB
MESOBLAST LIMITED ORDINARY
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 8.06% | — |
| 10 July | 8.11% | — |
| 9 July | 8.30% | — |
| 8 July | 8.39% | — |
| 7 July | 8.35% | — |
| 6 July | 8.37% | — |
| 3 July | 8.38% | — |
| 2 July | 8.38% | — |
| 1 July | 8.39% | — |
Mesoblast Limited (MSB) Short Interest Summary
Mesoblast Limited (MSB) currently has 8.06% of its shares sold short (104.3 million shares, worth approximately $289.0 million), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes MSB the #30 most shorted stock on the ASX most shorted list. Short interest in MSB is down 0.31% over the past week and down 0.82% over the past month. MSB is part of the Health Care sector on the ASX.
Recent MSB Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 8.06% | 104.3M | $2.35 |
| 10 July 2026 | 8.11% | 105.0M | $2.24 |
| 9 July 2026 | 8.30% | 107.4M | $2.10 |
| 8 July 2026 | 8.39% | 108.7M | $2.02 |
| 7 July 2026 | 8.35% | 108.1M | $2.04 |
| 6 July 2026 | 8.37% | 108.4M | $2.08 |
| 3 July 2026 | 8.38% | 108.4M | $2.06 |
| 2 July 2026 | 8.38% | 108.5M | $2.05 |
| 1 July 2026 | 8.39% | 108.6M | $2.04 |
| 30 June 2026 | 8.45% | 109.5M | $1.96 |
MSB Short Selling — Frequently Asked Questions
What is Mesoblast Limited (MSB)'s current short interest?
Mesoblast Limited (MSB) currently has a short interest of 8.06% of total shares outstanding. This means 8.06% of MSB's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is MSB heavily shorted on the ASX?
MSB has a moderate level of short interest at 8.06%. While below the heavily shorted threshold of 10%, this indicates notable bearish positioning. MSB is currently ranked #30 among the most shorted stocks on the ASX.
What does short interest mean for MSB investors?
Short interest in MSB shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 8.06%, MSB's short interest is at a moderate level. See our short squeeze candidates and days to cover analysis for more context.
Where does this MSB short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for MSB.